(CercleFinance.com) – OSE Immunotherapeutics announces today that the Company has received non-dilutive financing of €1.5 million from Bpifrance – Direction Régionale de Nantes.
This funding aims to accelerate the development of an innovative companion diagnostic test based on a simple blood sample.
It should make it possible to identify HLA-A2 positive patients with non-small cell lung cancer (NSCLC), eligible for treatment with Tedopi® (the vaccine against non-small cell lung cancer from OSE Immuno) in the next pivotal phase 3 clinical trial in preparation.
The objective of this final stage of clinical development is to confirm the efficacy and safety of Tedopi® as a second-line treatment after failure of checkpoint inhibitors (CPI) in patients with HLA-A2 positive NSCLC .